Nonalcoholic fatty liver disease (NAFLD) refers to a group of conditions characterized by hepatic steatosis in the absence of significant alcohol consumption. NAFLD is seen commonly in patients with metabolic abnormalities associated with obesity, such as type II diabetes, dyslipidemia, and metabolic syndrome. Evidently, however, not all obese subjects develop NAFLD and, more importantly, NAFLD can be found in nonobese individuals. Although NAFLD occurring in nonobese subjects has been reported in children and adults of all ethnicities, it appears to be recognized more frequently in Asians, even when strict ethnicityspecific body mass index criteria are used to define obesity. Studies based on liver biopsies suggest that the prevalence of nonalcoholic steatohepatitis and fibrosis does not differ significantly between nonobese NAFLD and NAFLD in obese patients. Visceral obesity as opposed to general obesity, high fructose and cholesterol intake, and genetic risk factors (eg, palatin-like phospholipase domain-containing 3) may be associated with nonobese NAFLD. In general, nonalcoholic steatohepatitis is associated with increased mortality, primarily from cardiovascular causes, independent of other metabolic factors. Although data regarding the mortality impact of nonobese NAFLD are not as mature, it may be important to identify high-risk nonobese NAFLD patients and manage their metabolic profile. Currently, lifestyle modification to reduce visceral adiposity, including dietary changes and physical activity, remains the standard of care in patients with nonobese NAFLD.
N onalcoholic fatty liver disease (NAFLD) is defined by the presence of steatosis in the liver without an alternate identifiable cause such as significant alcohol consumption. NAFLD encompasses a broad spectrum of pathology ranging from simple steatosis unaccompanied by inflammation or fibrosis to nonalcoholic steatohepatitis (NASH), and to cirrhosis and hepatocellular carcinoma. 1, 2 The global increase in the prevalence of obesity, type II diabetes, and metabolic syndrome has led to an increasing incidence of NAFLD. 3 NAFLD has been recognized as the most common liver disease in the Western world, with an estimated prevalence of 20% to 30%. 4 The increase of NAFLD has become a significant public health concern because NAFLD is associated with increased mortality from liver-related and liver-unrelated causes. 5, 6 Obesity is a common clinical phenotype associated with NAFLD, which is linked to metabolic syndrome and related comorbidities, including type II diabetes, hypertension, and dyslipidemia. Clearly, not all obese subjects develop NAFLD 7 and NAFLD also can be found in nonobese patients. 8 NAFLD may represent a group of conditions in which several pathogenetic processes may be in play that may be disparate between obese and nonobese patients, despite similar clinical and histopathologic presentation. Better understanding of the NAFLD occurring in a nonobese subject, for which we propose the term nonobese NAFLD or nonobese fatty liver disease, goes beyond a pursuit of academic curiosity. Questions of obvious practical importance may include the following: (1) what is the clinical significance of nonobese NAFLD as a liver disease, and (2) if nonobese NAFLD is a clinically significant condition, what are indicators to identify patients at risk? In this review, we attempt to address these questions by summarizing what is known and what remains unknown about nonobese NAFLD in the literature.
Prevalence
Globally, the reported prevalence of nonobese NAFLD varies widely, ranging from 3% to 30%. The variability may be attributed to differences in study subject selection, diagnostic modalities, and lifestyle and dietary customs of the specific population. The prevalence data on nonobese NAFLD between the East and West are not directly comparable at least in part because of the different body mass index (BMI) cut-off values for Asians. The recommended BMI cut-off value for Asians for being overweight is 23 to 25 kg/m 2 and for obesity is greater than 25 kg/m 2 , in contrast to 25 to 30 kg/m 2 and greater than 30 kg/m 2 , respectively, for subjects of other races. 9 The prevalence of nonobese NAFLD described in the literature is summarized in Table 1 . Although different studies used different BMI cut-off values, we attempt to align the definition of nonobese NAFLD to BMI less than 30 kg/m 2 for Western studies and BMI less than 25 kg/m 2 for Eastern studies. Among patients with nonobese NAFLD, lean NAFLD was defined as NAFLD in the population with a BMI less than 25 kg/m 2 for the Western studies and a BMI less than 23 kg/m 2 for Eastern studies. Most of the population-based studies that reported the prevalence of nonobese NAFLD in the West were conducted in the United States. The Dallas Heart Study measured the hepatic triglyceride content with proton nuclear magnetic resonance spectroscopy. 10 The prevalence of steatosis (defined as a hepatic triglyceride content > 5.5%) in subjects who were nonobese (BMI < 30 kg/m 2 ) was 17%, compared with 34%
in the overall study subjects. 10 The prevalence was not significantly different between nonobese Caucasians and nonobese Hispanics (20% vs 26%; P ¼ .12), whereas it was significantly lower in nonobese African Americans (11%). 10 The Multi-Ethnic Study of Atherosclerosis reported that the prevalence of nonobese NAFLD (BMI < 30 kg/m 2 ), as assessed by computed tomography, was 11%, including 9% among Caucasians, 6% among African Americans, and 18% among Hispanic Americans.
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The most generalizable data to the US population may come from the National Health and Nutrition Examination Survey (NHANES). Based on the NHANES III data collected from 1988 to 1994, 2 studies reported the prevalence of ultrasonography-detected hepatic steatosis to be 7% (moderate-severe hepatic steatosis) 12 and 21% (mild-severe hepatic steatosis) 13 among lean (BMI < 25 kg/m 2 ) participants without evidence of other liver disease. When the data were re-analyzed using a BMI cut-off value of 30 kg/m 2 , the prevalence increased to 27% (unpublished data). Finally, a northern Italian study (the Dionysus Study) used ultrasonography to determine steatosis in 257 subjects. 14 The prevalence of lean 14 The largest community-based study from the East was conducted in Korea. Kwon et al 15 reported the prevalence of nonobese NAFLD (BMI < 25 kg/m 2 ) to be 12.6% in 29,994 subjects presenting for a general medical examination. In a similar study analyzing 5878 nonobese (BMI < 25 kg/m 2 ), nondiabetic subjects, nonobese NAFLD was present in 27%. When a BMI cutoff value of less than 23 kg/m 2 was used, the prevalence of lean NAFLD remained high at 16%. 16 A study performed in rural India reported the prevalence of NAFLD in individuals with BMIs less than 23 kg/m 2 and less than 25 kg/m 2 of 5.5% and 7.4%, respectively. 8 In this population that included 47% with malnutrition, 75% of subjects with NAFLD had a BMI less than 25 kg/m 2 , and 54% were neither overweight nor had abdominal obesity. 8, 17 Xu et al 18 reported that the baseline prevalence of nonobese NAFLD (BMI < 25 kg/m 2 ) was 7.27% in China. In this cohort, a total of 5562 subjects who were free of nonobese NAFLD at baseline completed the follow-up study, and, of these subjects, 494 (8.88%) developed nonobese NAFLD during the 5-year follow-up period. 18 Finally, a population-based study in Hong Kong used magnetic resonance spectroscopy and detected steatosis in 19% of nonobese (BMI < 25 kg/m 2 ) subjects and in 61% with a higher BMI. 19 In summary, when the difference in the BMI cut-off value to determine obesity was taken into account, epidemiologic data from the West and the East indicated that 10% to 30% (7%-21% for Western studies [10] [11] [12] [13] [14] and 3%-27% for Eastern studies 8, 15, 16, [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] ) of nonobese individuals have evidence of steatosis and thus have nonobese NAFLD. Data from the East in patients with a very low BMI might suggest a pathogenetic process in operation in nonobese NAFLD that is different from NAFLD associated with obesity.
Histology
There are only limited data on the histology of nonobese NAFLD: morphologic features of nonobese NAFLD and obesity-associated NAFLD are presumed to be indistinguishable from each other, including a subset of patients showing features of NASH with or without fibrosis. Table 2 summarizes available data. 8, [29] [30] [31] [32] [33] [34] [35] [36] In a Belgian study that included 1777 patients undergoing a liver biopsy for chronic liver disease, nondiabetic nonobese NAFLD (BMI < 30 kg/m 2 ) was found in 2.8%. Of those, NASH and fibrosis were present in 61% and 55%, respectively, and there was less inflammation and fibrosis compared with obese NAFLD patients. 31 There were 2 other European studies that reported the presence of NASH in 50% and 65% of lean NAFLD patients, even when a lower BMI (<25 kg/m 2 ) cut-off value was used to select those patients. 29, 32 The prevalence of NASH was not associated with an increase in BMI (normal weight, 65%; overweight, 73%; and obese, 84%; P ¼ .184) in this study. 29 In these studies, the severity of inflammation and fibrosis did not differ significantly between nonobese NAFLD and obese NAFLD. A recent international study in abstract form reported that 11.5% were lean NAFLD (BMI < 25 kg/m 2 ) and 88.5% were overweight or obese NAFLD (BMI ! 25 kg/m 2 ) among 1090 patients with histology-confirmed NAFLD. 36 Patients with lean NAFLD had a lower degree of steatosis and less advanced fibrosis, but more severe lobular inflammation than the obese NAFLD. 36 Asian studies also have reported that NASH frequently is found in nonobese NAFLD. The rural Indian study mentioned previously included histologically diagnosed NASH in 31% and cirrhosis in 2.4% among NAFLD patients with increased liver enzyme levels, although the cohort was relatively young (mean age, 35.5 y) with a low BMI (mean, 19.6 kg/m 2 ). 8 Another study from Bangladesh reported that the prevalence of NASH (53% vs 47%) and fibrosis (20% vs 19%) was similar between patients with nonobese NAFLD and those with obese NAFLD. 34 A Chinese community cohort study using transient elastography showed that 2.6% of nonobese NAFLD patients and 5.1% of obese NAFLD patients had suspected advanced fibrosis (P ¼ .473), although liver stiffness was slightly lower in nonobese NAFLD patients (4.6 vs 5.6 kPa; P < .001). 19 Another recent histology-based study reported that patients with nonobese NAFLD (BMI < 25 kg/m 2 ) had a lower steatosis grade and presence in hepatocellular ballooning compared with obese NAFLD. 35 In this study, among nonobese patients, there was no difference in the histologic severity of NASH or fibrosis between lean NAFLD (BMI < 23 kg/m 2 ) and overweight NAFLD (BMI, 23-24.9 kg/m 2 ). 35 
Clinical Profile and Risk Factors for Nonobese Fatty Liver Disease
Features of the metabolic syndrome commonly associated with obesity do not affect all obese individuals, sparing approximately 10% to 30%. [37] [38] [39] These metabolic healthy but obese patients, despite having excessive body fat, have normal blood pressure and glucose metabolism, a favorable lipid profile, and low visceral and hepatic fat. [38] [39] [40] On the opposite end of the spectrum, some individuals with a normal BMI have metabolic abnormalities similar to those characteristically associated with obesity. 41 This subset of patients is called metabolically obese but normal weight (MONW), and show metabolic profiles characteristic of insulin resistance. 38, 42 In light of the well-known association between insulin resistance and NAFLD, nonobese NAFLD may represent a subset phenotype of NAFLD in MONW subjects. In the following sections, clinical, genetic, socioeconomic, and behavioral factors known to be associated with nonobese NAFLD are discussed.
Body Mass Index and Anthropometric Factors
The World Health Organization recommends BMI as a surrogate marker for physiological changes accompanying excess weight and obesity. However, it is well recognized that the impact of obesity varies widely at a given BMI. 43, 44 This is in part because factors such as age, sex, ethnicity, diet, and genetics play an important pathophysiological role in determining the metabolic abnormalities associated with obesity. Clearly, BMI is a crude marker of adiposity 45 compared, for example, with reference tests such as dual energy X-ray absorptiometry. 43, 44 BMI also fails to address body fat distribution. 46 It increasingly is recognized that among patients with a similar BMI, 39,46,47 distribution of fat in the abdominal area has important metabolic consequences. [48] [49] [50] Specifically, visceral abdominal adiposity, which is associated with the metabolic syndrome, is thought to be a key link to NAFLD. This is the reason why common anthropometric measurements such as the waist circumference may not be sufficient in assessing metabolic risks, it may not distinguish visceral vs subcutaneous adipose tissue. 51, 52 Visceral adipose tissue accounts for only 7% to 15% of total body fat; however, it plays a far more important role than subcutaneous fat in the pathogenesis of insulin resistance. 53 Portal venous blood contains free fatty acids and cytokines secreted by visceral adipose tissue, which is thought to drive the development of NAFLD. 54, 55 Visceral adiposity is especially relevant in MONW individuals, in whom not only a higher fat mass but also greater central adiposity and visceral fat drive their metabolic syndrome. 56, 57 Similarly, body fat distribution rather than the total body fat content may be much more important in the development of nonobese NAFLD. [58] [59] [60] [61] In a cohort study of 2017 subjects followed up for a median of 4.4 years after a health screen, the visceral adipose tissue area was associated with incident nonobese NAFLD in a dose-dependent manner. 62 In contrast, there was a significant inverse association between nonobese NAFLD and the subcutaneous adipose tissue area independent of visceral adiposity. 62 An emerging concept regarding subcutaneous fat is that it may act as a reservoir for metabolically neutral surplus lipids and might protect subjects against nonobese NAFLD by storing away excess calories. 63, 64 When the subcutaneous adipose tissue storage becomes saturated, fat deposits occur in other areas such as visceral adipose tissue and hepatocytes. 62, 64 Recently, sagittal abdominal diameter (SAD) has been proposed as an anthropometric indicator for visceral adiposity. SAD is measured by the anteroposterior diameter of the abdomen in the supine position, which displaces subcutaneous fat laterally by gravity. 51 SAD may have a stronger correlation with visceral adiposity than BMI or waist circumference, particularly among nonobese (BMI < 25 kg/m 2 ) and younger (age, <50 y) subjects compared with older obese subjects. 51 In contrast, waist circumference may be better correlated with subcutaneous adiposity than with visceral adiposity. 51 With regard to nonobese NAFLD, whether SAD is superior to other anthropometric measures in predicting visceral obesity remains to be determined.
Asians generally have a higher percentage of body fat and visceral fat compared with people of other races of the same age, sex, and even BMI. 9, 49, 65 Asian nonobese NAFLD patients have a higher body fat content and skinfold thickness and evidence of visceral adiposity compared with non-NAFLD subjects with a comparable BMI. 8 Lower BMI cut-off values have been suggested for the definition of metabolic syndrome in Asian individuals because of higher total body and visceral fat at any given BMI compared with those of other races. To what extent the new Asian definition for the metabolic syndrome would be instrumental in identifying patients with nonobese NAFLD remains to be determined. Table 3 summarizes clinical metabolic factors associated with nonobese NAFLD in various studies. 8, 13, 16, [19] [20] [21] 23, 28 It is apparent that metabolic risk factors associated with insulin resistance are relevant for nonobese NAFLD as they are for obese NAFLD. However, Kwon et al 15 suggested that the association with components of metabolic syndrome was stronger for nonobese NAFLD than for obese NAFLD. Patients with nonobese NAFLD had higher adjusted prevalence ratios for certain components (high triglyceride levels for both genders, high blood pressure, impaired fasting glucose level, and low high-density lipoprotein cholesterol for women) of metabolic syndrome than those with obese NAFLD. Nonobese NAFLD was associated with insulin resistance, regardless of the presence of other components of metabolic syndrome in nonobese, nondiabetic individuals. 16 Finally, several cohort studies have shown an association between weight gain within a nonobese BMI range and an incident nonobese NAFLD. 66 2 ) subjects, 368 (90.6%) of whom remained lean at the end of the follow-up period for a median of 47 months. 69 There were 29 (7.9%) who developed incident steatosis as determined by magnetic resonance. 69 Of a number of clinical and laboratory variables, increased waist circumference and serum triglyceride levels during the follow-up evaluation were found to be associated with incident fatty liver in their multivariable analysis. 69 Some of these patients did not fulfill the criteria for metabolic syndrome. 69 These data suggest that some of these susceptible individuals have low-grade insulin resistance and may be triggered into developing NAFLD with relatively small changes in their metabolic profile and that for those patients the current definitions for metabolic syndrome are not sensitive enough to characterize their metabolic risk. Conversely, these patients may benefit from weight loss, even when they may not have an abnormal BMI.
Metabolic Risk Factors

Dietary Composition
Cholesterol intake. Cholesterol metabolism may play a more significant role in the pathogenesis of nonobese NAFLD than in obese NAFLD because epidemiologic studies suggest that a high cholesterol diet is linked to nonobese NAFLD. In a small Italian study, higher cholesterol consumption was found in normal-weight NASH patients compared with BMI-matched controls. 70 A Japanese report found that although dietary intake of total energy, fat (including polyunsaturated fatty acids), and carbohydrates was markedly higher in obese NAFLD patients compared with the nonobese NAFLD patients and healthy volunteers, cholesterol intake was significantly higher in nonobese NAFLD patients than their obese NAFLD counterparts. 71, 72 Nonobese NAFLD can be established in animal models by feeding a high-cholesterol, normal calorie diet. [73] [74] [75] Cholesterol overload stimulates de novo lipogenesis by up-regulating expression of liver X receptor-a and activate fatty acid synthesis by increasing the level of oxysterol, a metabolite in the sterol-regulatory elementbinding protein-1c (SREBP-1c) pathway. 72, [76] [77] [78] Liver X receptor-a expression levels have been reported to be significantly higher in nonobese NAFLD compared with obese NAFLD. 72, 76 High cholesterol intake may cause nonobese NAFLD, even when the total caloric intake may not be excessive.
Whether the relationship between dietary cholesterol intake and nonobese NAFLD translates therapeutically remains to be determined. There has not been a dietary intervention study to lower cholesterol intake for the treatment of nonobese NAFLD. Cholesterol absorption inhibitors, such as ezetimibe, a Niemann-Pick C1 like 1 inhibitor, may reduce liver injury in nonobese NAFLD. 79 In obese NASH patients, however, a recent randomized controlled study failed to show that ezetimibe can significantly reduce liver fat. 80 Fructose ingestion. Consumption of soft drinks with added sugar, especially corn syrup fructose, has been linked to NAFLD. For example, a study based on the Israeli National Health and Nutrition Survey found that NAFLD patients consumed almost twice the amount of soft drinks as controls. Adjusting for age, sex, BMI, and total caloric intake, consumption of soft drinks was associated significantly with NAFLD (OR, 1.45; 95% CI, 1.13-1.85) compared with participants without NAFLD. 81 To the degree that nonobese NAFLD occurs at a younger age than NAFLD with obesity and that young adults tend to consume more soft drinks than older adults, fructose ingestion may play a larger role in patients with nonobese NAFLD than in obese NAFLD patients. 13 In a study of 31 nonobese NAFLD patients (mean age, 30 AE 13 y) without obvious risk factors (eg, diabetes, hyperlipidemia, or hypertension), nonobese NAFLD patients consumed higher amounts of added sugar (80% vs 20%). 82 Most of the added sugar (43%) in nonobese NAFLD patients came from soft drinks and juices, compared with only 8% in healthy controls. 82 When controlling for other factors including dietary composition and physical activity, soft drink consumption was the only independent risk factor for nonobese NAFLD. 82 In another multivariable analysis, soft drink consumption was associated significantly with fatty liver independent of metabolic syndrome and C-reactive protein levels. 83 From these results, fructose consumption may represent a readily modifiable environmental factor, particularly in young nonobese NAFLD patients, although interventional data are not available at the present time.
Genetic Risk Factors
Although visceral obesity, dietary preference, and insulin resistance are the most prevalent risk factors for nonobese NAFLD, hepatic fat varies substantially among subjects with equivalent adiposity, indicating that other factors contribute to nonobese NAFLD. Intrafamilial aggregation 84 and interethnic variations in susceptibility 10 suggest that genetic factors may be important in nonobese NAFLD.
Palatin-like phospholipase domain-containing 3. An analysis from the Dallas Heart Study found that a variant allele (rs738409) of palatin-like phospholipase domaincontaining 3 (PNPLA3) was associated strongly with hepatic triglyceride content. 85 Subsequent studies have replicated the observation, which strongly suggests that the polymorphism is an important genetic factor for NAFLD. The variant is associated not only with hepatic fat accumulation but also with susceptibility to more aggressive forms of NAFLD, such as NASH, fibrosis, and hepatocellular carcinoma. [86] [87] [88] The mechanism by which the PNPLA3 polymorphism may cause NAFLD remains incompletely understood. However, clinical epidemiologic data suggest that it is not mediated through insulin resistance and related metabolic comorbidities such as obesity, type 2 diabetes, or dyslipidemia. [89] [90] [91] [92] Thus, NAFLD may be seen in subjects with variant PNPLA3 without insulin resistance or adipose tissue inflammation. 92, 93 By the same token, patients with the variant allele may experience a more severe form of NAFLD, even if these metabolic abnormalities are absent as well.
These data suggest that the PNPLA3 variant may play an important role in the pathogenesis of nonobese NAFLD. A population-based study from Hong Kong showed that a greater proportion of patients with nonobese NAFLD carried the variant PNPLA3 allele than those with obese NAFLD (78.4% vs 59.8%) and the PNPLA3 polymorphism remained an independent risk factor for nonobese NAFLD, after adjusting for other covariates such as insulin resistance. 19 Data are lacking, however, as to what extent the genetic variant contributes to nonobese NAFLD in an individual patient or in a population.
Cholesteryl ester transfer protein. The cholesteryl ester transfer protein (CETP) may be important in the pathogenesis of NAFLD. CETP plays a critical role in reverse cholesterol transport, the process by which cholesterol moves from peripheral tissue back to the liver. 94 Adams et al 95 reported that 2 single-nucleotide polymorphisms on the gene, namely rs12447924 and rs12597002, are associated with an increased risk of fatty liver. Relevant to the current discussion, the risk of NAFLD associated with the CETP polymorphisms was most pronounced in nonobese individuals. 95 In variant homozygotes who were nonobese or without central obesity, the prevalence of fatty liver remained high (28% and 33%, respectively, for rs12447924, and 25% and 29%, respectively, for rs12597002), whereas only 3% to 5% nonvariant homozygote individuals had fatty liver.
Sterol regulatory element-binding factor 2. The sterol regulatory element-binding factor (SREBF) gene codes for SREBP-2, which regulates genes involved in cellular cholesterol biosynthesis, uptake, and excretion. 96 Hepatic up-regulation of SREBP-2 parallels the severity of NAFLD. 97 A recent prospective cohort study assessed the impact of a SREBF-2 polymorphism (rs133291) on the risk of developing nonobese NAFLD and on liver histology. 98 The SREBF-2 polymorphism was associated with the development of NAFLD in nonobese, nondiabetic patients without the metabolic syndrome. 98 The 7-year incidence of nonobese NAFLD in subjects with variant SREBF was 38%, compared with 21% in those with the wild type. 98 In addition, among patients with biopsy-proven nonobese NAFLD, SREBF-2 was associated with higher odds of NASH (OR, 2.9; 95% CI, 2.1-4.2).
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Transmembrane 6 superfamily member 2. A singlenucleotide polymorphism in transmembrane 6 superfamily member 2 (TM6SF2) was associated with hepatic triglyceride content in the Dallas Heart Study. 99 Subsequently, this TM6SF2 minor allele was found to be associated with hepatic fibrosis independent of age, diabetes, obesity, and the PNPLA3 genotype. 100 The association between TM6SF2 minor allele and various NAFLD phenotypes has been reproduced in several studies, 101, 102 even though data regarding the genetic impact of TM6SF2 on nonobese NAFLD are not as mature.
Prognosis
In contrast to risk factors of nonobese NAFLD, data on the prognosis of nonobese NAFLD have been scarce until now. In an analysis using the NHANES III, metabolic syndrome was an independent predictor of all-cause mortality among patients with NAFLD, although obesity (BMI ! 30 kg/m 2 ) was not associated with overall mortality in patients with NAFLD. 103 This result may be speculated for nonobese NAFLD, which may represent a subset phenotype of NAFLD in MONW subjects. A recent international study mentioned previously reported patients with lean NAFLD have a higher overall mortality than patients with obese NAFLD (P < .02) over a followup period of 11 years, despite presenting with a healthier metabolic profile such as lower insulin resistance. 36 A recent study from Hong Kong showed that clinical events developed in 12% of obese NAFLD and 8% of nonobese NAFLD (P ¼ . 19 ), but all mortality (4%) occurred in patients with obese NAFLD, despite a relatively shortterm follow-up period (median, 49 mo) in this study. 35 Further studies appear to be warranted to determine the prognosis and natural history in patients with nonobese NAFLD.
Diagnosis
NAFLD is defined by fatty infiltration of the liver as determined either by imaging or by histology after the exclusion of significant alcohol consumption or other known secondary causes (viral hepatitis such as genotype 3 hepatitis C, medication with a known association with fatty liver, lipodystrophy, and so forth). 104 NASH is characterized by hepatic fat infiltration plus evidence of inflammation: ballooning degeneration and/or fibrosis. For the purpose of this review, nonobese NAFLD may be diagnosed when NAFLD, including NASH, is present by imaging in subjects with a nonobese BMI, as assessed by the ethnic-specific BMI cut-off values.
Despite progress in imaging tools to diagnose hepatic steatosis, no imaging modality currently is available to differentially diagnose NASH from simple steatosis. Of components of NASH, fibrosis is clinically the most important because advanced fibrosis affects clinical outcomes such as mortality. [105] [106] [107] Several noninvasive serum panels to diagnose advanced fibrosis have been evaluated in patients with NAFLD, including the Fibrosis-4 (FIB-4) and NAFLD fibrosis scores. [108] [109] [110] In particular, the NAFLD fibrosis score has been validated in 13 studies, including 2 multicenter trials in the United States and Japan that enrolled a total of 3064 patients of different race, age, BMI, and diabetes status. 109 Although this score is based on standard BMI criteria, its accuracy is maintained in studies in East Asian cohorts that contain subjects with a lower BMI in excluding advanced fibrosis.
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For a more accurate diagnosis of fibrosis, 2 physical modalities, namely, transient elastography 114, 115 and magnetic resonance elastography, 116,117 may be useful. Of the 2, transient elastography may be particularly useful in patients with nonobese NAFLD because it is subject to technical failure in obese individuals, with an approximately 20% failure rate when BMI is greater than 30 kg/m 2 . 118 However, there have been few studies to date on the use of elastography in the diagnosis of NASH with advanced fibrosis in the nonobese population.
Treatment
At present, in the absence of approved pharmacologic therapy, the current treatment for NAFLD remains weight loss with lifestyle modification. The American Association for the Study of Liver Diseases practice guideline state that loss of at least 3% to 5% of body weight may be necessary to improve NAFLD. 119 The same may be true for nonobese NAFLD. As previously noted, because weight gain even within the nonobese BMI range is associated with the development of nonobese NAFLD, weight loss may lead to remission of nonobese NAFLD. 66, 67 In a population-based intervention study conducted in Asian patients whose mean BMI was 25 kg/m 2 , 97% of patients who lost more than 10% of their body weight achieved resolution of NAFLD, whereas approximately 40% of patients with a 3% to 5% weight loss of their body weight did. 120 Another recent study with paired biopsy data showed that improvement in liver histology from weight reduction by lifestyle modification was similar between potential living liver donors with nonobese NAFLD and those with obese NAFLD. 121 However, detailed data to direct lifestyle modification specifically in nonobese NAFLD patients remain insufficient.
Emerging data indicate that NAFLD patients with variant PNPLA3 alleles may benefit more from lifestyle modification than those with other genotypes. 122 For examples, the degree to which weight loss decreased intrahepatic triglyceride contents 123 and liver enzyme levels 124 was larger in subjects with homozygous GG than in those with homozygous CC. The mechanism for these observations remain unclear, although it has been suggested that PNPLA3 polymorphisms may affect metabolic responses (eg, insulin sensitivity) to weight loss, modulating liver damage more effectively. 123, 124 Because Asian patients with nonobese NAFLD are more likely to be carriers of the G allele, 19 the effect of lifestyle modification may be more pronounced in nonobese Asians. 69 Lifestyle modification and weight loss resulting in reduction in visceral obesity should be suggested for all patients with nonobese NAFLD.
Increased physical activity may have a beneficial effect on nonobese NAFLD by helping to reduce visceral fat. Several studies instituting physical activity interventions have suggested that a reduction in visceral fat is a prerequisite for a reduction in steatosis, [125] [126] [127] although conflicting data exist. [128] [129] [130] Although there is no study to evaluate the effectiveness of physical activity exclusively in patients with nonobese NAFLD, a large cross-sectional study in Asia of patients whose BMIs were 23.7 AE 3.0 kg/m 2 showed an inverse association between total and leisure-time physical activities and the prevalence of NAFLD, independent of visceral adiposity and insulin resistance. 131 We believe that increased physical activity is an important component of lifestyle modification in patients with nonobese NAFLD irrespective of visceral obesity or insulin resistance.
Conclusions
Nonobese NAFLD occurs in children and adults of all ethnicities, although it appears to be more common among Asians, even when the strict ethno-specific criteria for obesity are applied. Likely risk factors for nonobese NAFLD include visceral instead of general obesity, body weight gain even within normal weight limits, high fructose and high cholesterol intake, and genetic risk factors (eg, PNPLA3 and TM6SF2). Available epidemiologic data have shown that the prevalence of NASH and advanced fibrosis does not differ significantly between nonobese NAFLD and obese NAFLD. Although the natural history of nonobese NAFLD has not been studied widely, it is important to identify individuals at risk for nonobese NAFLD, who lack the easily recognizable phenotype of obesity. Furthermore, patients with nonobese NAFLD must be further risk-stratified because advanced fibrosis adversely affects future outcomes. Currently, lifestyle modification, including diet and physical activity targeting visceral adiposity, remains the mainstay in the management of patients with nonobese NAFLD, although the pharmaceutical agents being studied for NAFLD in general also may be effective for nonobese NAFLD in the future.
